Comparative Study of Ologen Collagen Matrix Versus Mitomycin-C in Glaucoma Filtering Surgery (MCToCM)

Aeon Astron

Status and phase: Completed; Phase 4

Conditions: Glaucoma

Treatments: Drug: Use of Mitomycin-C (MMC) in trabeculectomy; Device: Use of ologen Collagen Matrix in trabeculectomy (ologen)

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01440751

AAE-CT-USA-2010-02

Details and patient eligibility

About

The objective of this prospective randomised study is to compare the efficacy and safety of ologen CM (Collagen matrix) and Mitomycin-C (MMC) as adjuncts to filtration surgery in uncontrolled treated glaucoma cases, the efficacy being the primary objective and the safety being the secondary.

Full description

"ologen ® CM" is a biodegradable collagen matrix. To prevent episcleral fibrosis and subconjunctival scarring thay may result in the surgical failure in trabeculectomy, its sporous matrix modulates the migrations and proliferations of fibroblasts to create a vascular and long-lasting bleb without the adverse effects, such as avascular thin bleb wall, bleb leak, hypotony, and inflammations, potentially caused by the regeneration suppression effects upon the use of cytotoxic agents as anti-fibrotic agents, such as MMC (Mitomycin-C)in the study.

Results of ologen CM studies have been published at conferences and published in peer-reviewed journals; ologen CM is approved in Europe as an aid for tissue repair, and by the FDA in the US as an adjunct in wound management(K080868). In general, over 6,000 ologen CM have been implanted worldwide during the past two years with good results and excellent safety profile.

The clinical trial is a phase-IV post-marketing FDA approved device study designed as open-label, randomised, parallel, and comparative. 128 patients at 8 sites are anticipated to be recruited according to the enrollment criteria, while randomisation will be assigned by a sealed envelope system after the patient has signed consent. Trabeculectomy is performed thereafter with either MMC or ologen CM applications as described in the protocol with postoperative parameters to be measured and analysed with non-parametric tests(Chi-square, Fisher's exact, Wilcoxon, and Mann-Whitney tests) as well as Kaplan-Meier survival models.

Enrollment: 99 patients

Sex: All

Ages: 30+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age > 30 years (inclusive)
• Uncontrolled treated glaucoma requiring trabeculectomy
• Subject must be able and willing to cooperate with investigation plan
• Subject must be able and willing to complete postoperative follow-up requirements
• subject must be willing to sign informed consent form

Exclusion criteria

• Known allergic reaction to MMC or porcine collagen
• Neovascular, uveitic, aphakic glaucoma, previous incisional glaucoma surgery
• Prior cataract unless clear corneal incision
• Previous conjunctival or strabismus surgery
• Participation in an investigational study during 30 days prior to trabeculectomy
• Ocular infection within 14 days prior to trabeculectomy
• Pregnant or breast-feeding women

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

99 participants in 2 patient groups

ologen Collagen Matrix

Experimental group

Description:

When performing glaucoma surgery, a trabeculectomy, use ologen Collagen Matrix instead of MMC before closing the conjunctiva

Treatment:

Device: Use of ologen Collagen Matrix in trabeculectomy (ologen)

Mitomycin-C (MMC)

Active Comparator group

Description:

When performing glaucoma surgery, a trabeculectomy, use MMC as antifibrotic agent before closing the conjunctiva

Treatment:

Drug: Use of Mitomycin-C (MMC) in trabeculectomy